NCT05057676

Brief Summary

The goal of this project is to critically evaluate the effectiveness of using an online program to improve diet and self-care in patients with multiple sclerosis (MS), clinically isolated syndrome (CIS), fibromyalgia, post acute sequela of covid, and cancer in remission with persisting fatigue.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for not_applicable multiple-sclerosis

Timeline
20mo left

Started Dec 2021

Longer than P75 for not_applicable multiple-sclerosis

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Dec 2021Dec 2027

First Submitted

Initial submission to the registry

September 15, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 27, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2021

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

March 11, 2026

Status Verified

March 1, 2026

Enrollment Period

6 years

First QC Date

September 15, 2021

Last Update Submit

March 9, 2026

Conditions

Keywords

dietself care

Outcome Measures

Primary Outcomes (8)

  • Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)

    Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

    baseline to 3 months

  • Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)

    Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

    baseline to 6months

  • Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)

    Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

    baseline to 3 months

  • Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)

    Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

    baseline to 6 months

  • Short form 36 (SF 36)

    Change in (SF 36) survey questions mean scores, range 0-100, higher number is better.

    baseline to 3 months

  • Short form 36 (SF 36)

    Change in (SF 36) survey questions mean scores, range 0-100, higher number is better.

    baseline to 6 months

  • The Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-FS):

    FACIT-FS is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function, which can be completed in less than 5 minutes.10 Each question provides 5 ordinal response options ("not at all," "a little bit," "somewhat," "quite a bit," and "very much"). Each item contributes equally (item score range=0-4) to a total score that ranges from 0 to 52, where higher scores represent less fatigue.

    baseline to 3 months

  • The Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-FS):

    FACIT-FS is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function, which can be completed in less than 5 minutes.10 Each question provides 5 ordinal response options ("not at all," "a little bit," "somewhat," "quite a bit," and "very much"). Each item contributes equally (item score range=0-4) to a total score that ranges from 0 to 52, where higher scores represent less fatigue.

    baseline to 6 months

Secondary Outcomes (21)

  • Modified Fatigue Impact Scale

    baseline to 3 months

  • Modified Fatigue Impact Scale

    baseline to 6 months

  • vegetable and fruit intake

    baseline to 3 months

  • vegetable and fruit intake

    baseline to 6 months

  • added sugar intake

    baseline to 3 months

  • +16 more secondary outcomes

Study Arms (2)

Intervention Autoimmune Intervention Mastery Course (AIM) online course

EXPERIMENTAL

This arm will begin the intervention immediately after randomization

Behavioral: Immediate Autoimmune Intervention Mastery Course (AIM)Behavioral: Immediate Question and Answer sessions. (AIM Q and A sessions)

Delayed Autoimmune Intervention Mastery Course

OTHER

This is the control arm.

Behavioral: Delayed Autoimmune Intervention Mastery Course (delayed AIM course)Behavioral: Delayed AIM Question and Answer sessions

Interventions

Immediate access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care

Also known as: AIM course
Intervention Autoimmune Intervention Mastery Course (AIM) online course

Immediate access to videos answering common questions about the course concepts. One video released each week, 7 videos total.

Also known as: AIM Q and A sessions
Intervention Autoimmune Intervention Mastery Course (AIM) online course

Delayed access to an on line audio and video course with education about strategies to grow and improve resilience, diet quality, exercise, stress reduction and self-care

Delayed Autoimmune Intervention Mastery Course

Delayed access to videos answering common questions about the course concepts. One video released each week, 7 videos total.

Also known as: Delayed AIM Q and A sessions
Delayed Autoimmune Intervention Mastery Course

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • self-reported multiple sclerosis
  • self-reported clinically isolated syndrome
  • OR self-reported post-acute sequelae of COVID (PASC), also known as long COVID, with a confirmed laboratory test of COVID-19 infection, persisting fatigue and neuropsychiatric symptoms for longer than 6 months after confirmation of COVID diagnosis,
  • OR self-reported diagnosis of fibromyalgia as documented by their treating specialist or primary care provider,

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Univeristy of Iowa

Iowa City, Iowa, 52246, United States

RECRUITING

Related Publications (10)

  • Wahls TL, Chenard CA, Snetselaar LG. Review of Two Popular Eating Plans within the Multiple Sclerosis Community: Low Saturated Fat and Modified Paleolithic. Nutrients. 2019 Feb 7;11(2):352. doi: 10.3390/nu11020352.

    PMID: 30736445BACKGROUND
  • Wahls T, Scott MO, Alshare Z, Rubenstein L, Darling W, Carr L, Smith K, Chenard CA, LaRocca N, Snetselaar L. Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial. Trials. 2018 Jun 4;19(1):309. doi: 10.1186/s13063-018-2680-x.

    PMID: 29866196BACKGROUND
  • Chenard CA, Rubenstein LM, Snetselaar LG, Wahls TL. Nutrient Composition Comparison between a Modified Paleolithic Diet for Multiple Sclerosis and the Recommended Healthy U.S.-Style Eating Pattern. Nutrients. 2019 Mar 1;11(3):537. doi: 10.3390/nu11030537.

    PMID: 30832289BACKGROUND
  • Titcomb TJ, Bisht B, Moore DD 3rd, Chhonker YS, Murry DJ, Snetselaar LG, Wahls TL. Eating Pattern and Nutritional Risks among People with Multiple Sclerosis Following a Modified Paleolithic Diet. Nutrients. 2020 Jun 20;12(6):1844. doi: 10.3390/nu12061844.

    PMID: 32575774BACKGROUND
  • Wahls TL, Titcomb TJ, Bisht B, Eyck PT, Rubenstein LM, Carr LJ, Darling WG, Hoth KF, Kamholz J, Snetselaar LG. Impact of the Swank and Wahls elimination dietary interventions on fatigue and quality of life in relapsing-remitting multiple sclerosis: The WAVES randomized parallel-arm clinical trial. Mult Scler J Exp Transl Clin. 2021 Jul 31;7(3):20552173211035399. doi: 10.1177/20552173211035399. eCollection 2021 Jul-Sep.

    PMID: 34377527BACKGROUND
  • Lee JE, Titcomb TJ, Bisht B, Rubenstein LM, Louison R, Wahls TL. A Modified MCT-Based Ketogenic Diet Increases Plasma beta-Hydroxybutyrate but Has Less Effect on Fatigue and Quality of Life in People with Multiple Sclerosis Compared to a Modified Paleolithic Diet: A Waitlist-Controlled, Randomized Pilot Study. J Am Coll Nutr. 2021 Jan;40(1):13-25. doi: 10.1080/07315724.2020.1734988. Epub 2020 Mar 26.

    PMID: 32213121BACKGROUND
  • Bisht B, Darling WG, Grossmann RE, Shivapour ET, Lutgendorf SK, Snetselaar LG, Hall MJ, Zimmerman MB, Wahls TL. A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. J Altern Complement Med. 2014 May;20(5):347-55. doi: 10.1089/acm.2013.0188. Epub 2014 Jan 29.

    PMID: 24476345BACKGROUND
  • Bisht B, Darling WG, White EC, White KA, Shivapour ET, Zimmerman MB, Wahls TL. Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study. Degener Neurol Neuromuscul Dis. 2017 Jun 26;7:79-93. doi: 10.2147/DNND.S128872. eCollection 2017.

    PMID: 30050380BACKGROUND
  • Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG. Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study. Degener Neurol Neuromuscul Dis. 2017 Jan 4;7:1-18. doi: 10.2147/DNND.S116949. eCollection 2017.

    PMID: 30050374BACKGROUND
  • Titcomb TJ, Sherwood M, Ehlinger M, Saxby SM, Shemirani F, Eyck PT, Wahls TL, Snetselaar LG. Evaluation of a web-based program for the adoption of wellness behaviors to self-manage fatigue and improve quality of life among people with multiple sclerosis: A randomized waitlist-control trial. Mult Scler Relat Disord. 2023 Sep;77:104858. doi: 10.1016/j.msard.2023.104858. Epub 2023 Jun 27.

MeSH Terms

Conditions

Multiple SclerosisFibromyalgiaPost-Acute COVID-19 Syndrome

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesMuscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesCOVID-19Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesPost-Infectious DisordersChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Terry L Wahls, MD

    University of Iowa

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Masking Details
Investigator will be masked.
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Model Details: Wait list control
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Clinical professor

Study Record Dates

First Submitted

September 15, 2021

First Posted

September 27, 2021

Study Start

December 1, 2021

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

March 11, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations